Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
1081 Naloxone HCl 0.02mg/ml Injection V03AB15-110-P30-01-XX B For the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis of suspected acute opioids overdosage None 0.005 - 0.01 mg/kg body weight repeated at intervals of 2 - 3 minutes according to the patient's needs by IM, IV or SC
1082 Naloxone HCl 0.4mg/ml Injection V03AB15-110-P30-02-XX B For the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis of suspected acute opioids overdosage None Initially 0.4 - 2 mg IV repeated at intervals of 2 - 3 minutes according to patient's needs
1083 Naltrexone HCl 50 mg Tablet N07BB04110T1001XX A Adjunct in relapse prevention treatment in detoxified formerly opioid-dependant patients Initial 25 mg may be increased to 50 mg. Maintenance: 350 mg weekly; administered as 50 mg daily. Dosing interval may be lengthened to improve compliance; 100 mg on alternate days or 150 mg every third day
1084 Naproxen 250mg Tablet M01AE02-000-T10-01-XXX A/KK i) Rheumatic arthritis, osteoarthritis and ankylosing spondylitis
ii) Acute gout
iii) Muscular skeletal disorder, dysmenorrhoea		 None i) 0.5 - 1 g daily in 2 divided doses
ii) 750 mg initially then 250 mg 8 hourly
iii) 500 mg initially then 250 mg every 6 - 8 hour as required

Max: 1g daily
1085 Naproxen Sodium 275mg Tablet M01AE02-520-T10-01-XXX A i) Rheumatic arthritis, osteoarthritis and alkylosing spondylitis
ii) Acute gout
iii) Muscular skeletal disorder and dysmenorrhoea		 None i: 275mg bd
ii: Initial: 825mg followed by 275mg every 8 hrs as necesssary
iii. Initial: 550mg followed by 275 every 6-8 hrs as necessary.
1086 Neomycin 0.5% Cream D06AX04256G1001XX B Infections of the skin due to susceptible organisms Apply sparingly to affected area up to 3 times daily (For short term use, 1 - 2 weeks)
1087 Neomycin 0.5% in Betamethasone 17-Valerate 0.01% Cream D07CC01-947-G10-01-XXX B Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo None Apply sparingly to affected area 2 - 3 times daily. (May cause sensitisation to neomycin. Use with caution)
1088 Neomycin 0.5% in Betamethasone 17-Valerate 0.01% Ointment D07CC01-947-G50-01-XXX B Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo None Apply sparingly to affected area 2 to 3 times daily. (May cause sensitisation to Neomycin. Use with caution)
1089 Neomycin 0.5% in Betamethasone 17-Valerate 0.1% Cream D07CC01-947-G10-02-XXX A Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo None Apply sparingly to affected area 2 - 3 times daily (May cause sensitisation to neomycin. Use with caution)
1090 Neomycin 0.5% in Betamethasone 17-Valerate 0.1% Ointment D07CC01-947-G50-02-XXX A Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo Apply sparingly to affected area 2 to 3 times daily. (May cause sensitisation to neomycin. Use with caution)
1091 Neomycin 0.5% Ointment D06AX04256G5001XX B Infections of the skin due to susceptible organisms Apply sparingly to affected area up to 3 times daily (For short term use, 1- 2 weeks)
1092 Neostigmine Methylsulphate 2.5mg/ml Injection N07AA01-183-P30-02-XXX B i) Symptomatic treatment of myasthenia gravis where oral therapy is impractical
ii) Reversal of the effects of non-depolarizing neuromuscular blockade
iii)The management of post-operative distension, paralytic ileus and urinary retention, where mechanical obstruction has been out-ruled		 i) ADULT: 1 - 2.5 mg at suitable intervals by SC, IM or IV. Usual total daily dose 5 - 20 mg.
CHILD: 0.1mg IM. Titrated in the range of 0.05mg - 0.25mg.
NEONATE: 50 - 250 mcg every 4 hours
ii) By IV injection over 1 minute, 50 - 70 mcg/kg (maximum 5 mg and 2.5mg for children) after or with atropine sulphate 0.6 - 1.2 mg
iii) Adults: SC or IM 0.5 - 2.5mg. Children: SC or IM 0.125mg - 1mg
1093 Nepafenac 0.1% ophthalmic solution S01BC10-000-D20-01-XXX A* Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients. None One drop 3 times/day beginning 1 day prior to cataract surgery, continued on the day of surgery and up to 60 days of the postoperative period as directed by the clinician.
An additional drop should be administered 30 to 120 minutes prior to surgery.
1094 Netilmicin Sulphate 100 mg/2 ml Injection J01GB07183P3002XX A Systemic infections ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day
1095 Netilmicin Sulphate 150 mg/2 ml Injection J01GB07183P3003XX A Systemic infections ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day
1096 Netilmicin Sulphate 50 mg/2 ml Injection J01GB07183P3001XX A Systemic infections ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day
1097 Neuro Polyvalent Snake Antivenom Injection Nil B Passive immunisation against poisonous of a range of haematotoxic snakebites neurotoxic snakebites, based on the type of snake identified. For initial dose, at least 20mL of reconstituted serum should be given by slow intravenous infusion (not more than 1mL/minute). If symptoms still persist, the second dose should be repeated 2 hours or even earlier after the initial dose. The further dose should be repeated every 6 hours according to the clinical symptoms.

Administration: Draw 10mL of the sterile water for injection to the freeze-dried antivenin, shake well to dissolve the contents until the serum became clear colourless or pale yellow liquid, ready for administration.
1098 Nevirapine 200mg Tablet J05AG01-000-T10-01-XXX A/KK Treatment of HIV-1 infection in combination with other antiretroviral agents None Combined with other antiretrovirals: 200 mg once daily for the 1st 14 days; up to 200 mg twice daily if rash does not develop. Re-introduce at a lower dose for the 1st 14 days if treatment is interrupted for >7 days,necessitate reintroduction at a lower dose for the first 14 days.
1099 Nevirapine 50mg/5ml Oral Suspension J05AG01-000-L80-01-XXX A/KK Treatment of HIV-1 infection in combination with other antiretroviral agents None The total daily dose should not exceed 400mg.
Nevirapine may be dosed in paediatric patients either by body surface area (BSA) or by body weight.
i)By BSA using the Mosteller formula: the recommended oral dose for paediatric patients of all ages is 150 mg/m2 once daily for 2 weeks followed by 150 mg/m2 twice daily thereafter.
ii)By body weight:
<8 years of age: 4 mg/kg once daily for 2 weeks followed by 7 mg/kg twice daily thereafter.
≥8 years: 4 mg/kg once daily for 2 weeks followed by 4 mg/kg twice daily thereafter.
1100 Nicardipine Hydrochloride 1mg/ml Solution for Infusion C08CA04-110-P31-01-xxx A Treatment of hypertensive crisis None i) Adult Dose

Initial dose
Treatment should start with the continuous administration of nicardipine at a rate of 3-5 mg/h for 15 minutes. Rates can be increased by increments of 0.5 or 1 mg every 15 minutes. The infusion rate should not exceed 15 mg/h.

Maintenance dose 
When the target pressure is reached, the dose should be reduced progressively, usually to between 2 and 4 mg/h, to maintain the therapeutic efficacy.

ii) Paediatric Dose
Nicardipine should only be used for life-threatening hypertension in paediatric intensive care settings or postoperative contexts.

Initial dose:
In case of emergency, a starting dose of 0.5 to 5 mcg/kg/min is recommended.

Maintenance dose:
The maintenance dosage of 1 to 4mcg/kg/min is recommended
1101 Nicotine 1 mg/spray Mouth Spray N07BA01-000-A42-01-xxx A/KK For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. None 1 mg of nicotine per metered spray dose, up to 3 sprays per hour for administration into the oral cavity
1102 Nicotine 10mg/16hr Transdermal Patch N07BA01000M7005XX A/KK For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. The patch should be apply to an intact area of the skin upon waking up in the morning and removed at bedtime.

Heavy smoker (those smoking 15 or more cigarettes in a 24-hour period):
Step 1: 25mg/16 hours patch and use one patch daily for 8 weeks.
Step 2: One 15mg/16hours patch should be daily for 2 weeks
Step 3: One 10mg/16 hours patch daily for 2 weeks.

Light smokers (those smoking less than 15 cigarettes in a 24-hour period):
Step 1: 15mg/16hours patch for 8 weeks
Step 2: 10mg/16hours for the final 4 weeks.

Combination therapy with the patch (Flexible smoking cessation format) for fast relief of cravings in:
i) Highly dependent smokers; or
ii) Smokers who experience breakthrough cravings; or
iii) Those who have failed single NRT treatment
1103 Nicotine 14mg/24hr Transdermal Patch N07BA01000M7002XX A/KK For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. The patch should be apply to an intact area of the skin upon waking up in the morning and removed at 24hrs.

Smokers of >10 cigarettes/day:
21 mg/day for 6 wk, then 14 mg/day for 2 wk; finish w/ 7 mg/day for 2 wk.

Smokers of ≤10 cigarettes/day:
14 mg/day for 6 wk, then 7 mg/day for 2 wk.
1104 Nicotine 15mg/16hr Transdermal Patch N07BA01000M7006XX A/KK For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. The patch should be apply to an intact area of the skin upon waking up in the morning and removed at bedtime.

Heavy smoker (those smoking 15 or more cigarettes in a 24-hour period):
Step 1: 25mg/16 hours patch and use one patch daily for 8 weeks.
Step 2: One 15mg/16hours patch should be daily for 2 weeks
Step 3: One 10mg/16 hours patch daily for 2 weeks.

Light smokers (those smoking less than 15 cigarettes in a 24-hour period):
Step 1: 15mg/16hours patch for 8 weeks
Step 2: 10mg/16hours for the final 4 weeks.

Combination therapy with the patch (Flexible smoking cessation format) for fast relief of cravings in:
i) Highly dependent smokers; or
ii) Smokers who experience breakthrough cravings; or
iii) Those who have failed single NRT treatment.
1105 Nicotine 21mg/24hr Transdermal Patch N07BA01000M7003XX A/KK For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. The patch should be apply to an intact area of the skin upon waking up in the morning and removed at 24hrs.

Smokers of >10 cigarettes/day:
21 mg/day for 6 wk, then 14 mg/day for 2 wk; finish w/ 7 mg/day for 2 wk.

Smokers of ≤10 cigarettes/day:
14 mg/day for 6 wk, then 7 mg/day for 2 wk.
1106 Nicotine 25mg/16hr Transdermal Patch N07BA01-000-M70-07-001 A/KK For the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms thereby facilitating smoking cessation in smokers motivated to quit. Advice and support normally improve the success rate. The patch should be apply to an intact area of the skin upon waking up in the morning and removed at bedtime.

Heavy smoker (those smoking 15 or more cigarettes in a 24-hour period):
Step 1: 25mg/16 hours patch and use one patch daily for 8 weeks.
Step 2: One 15mg/16hours patch should be daily for 2 weeks
Step 3: One 10mg/16 hours patch daily for 2 weeks.

Light smokers (those smoking less than 15 cigarettes in a 24-hour period):
Step 1: 15mg/16hours patch for 8 weeks
Step 2: 10mg/16hours for the final 4 weeks.

Combination therapy with the patch (Flexible smoking cessation format) for fast relief of cravings in:
i) Highly dependent smokers; or
ii) Smokers who experience breakthrough cravings; or
iii) Those who have failed single NRT treatment.
1107 Nicotine 2mg Gum N07BA01000M9901XX A/KK For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. Smokes ≤ 20 sticks/day, chew 2mg gum.
Smokes ≥ 20 sticks/day,chew 4 mg gum. (MAX 24 pieces /day for up to 12 week.)
1108 Nicotine 4mg Gum N07BA01000M9902XX A/KK For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. Smokes ≤ 20 sticks/day, chew 2mg gum.
Smokes ≥ 20 sticks/day, chew 4 mg gum. (MAX 24 pieces /day for up to 12 week.)
1109 Nicotine 7mg/24hr Transdermal Patch N07BA01000M7001XX A/KK For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. The patch should be apply to an intact area of the skin upon waking up in the morning and removed at 24hrs.

Smokers of >10 cigarettes/day:
21 mg/day for 6 wk, then 14 mg/day for 2 wk; finish w/ 7 mg/day for 2 wk.

Smokers of ≤10 cigarettes/day:
14 mg/day for 6 wk, then 7 mg/day for 2 wk.
1110 Nicotinic Acid 50 mg Tablet A11HA01000T1001XX B For prophylaxis and treatment of Vitamin B3 deficiency Prophylactic: 15 - 30 mg daily. Therapeutic: 50 - 250 mg daily. Maximum single dose: 200 mg. Maximum dose in 24 hours: 800 mg

Halaman-halaman